Research Papers:

Human papillomavirus infection as a prognostic marker for lung adenocarcinoma: a systematic review and meta-analysis

Lanwei Guo, Shuzheng Liu, Shaokai Zhang, Qiong Chen, Meng Zhang, Peiliang Quan and Xibin Sun _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:34507-34515. https://doi.org/10.18632/oncotarget.15671

Metrics: PDF 1889 views  |   HTML 2022 views  |   ?  


Lanwei Guo1, Shuzheng Liu1, Shaokai Zhang1, Qiong Chen1, Meng Zhang1, Peiliang Quan1 and Xibin Sun1

1Department of Cancer Epidemiology, Henan Office for Cancer Control and Research, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China

Correspondence to:

XiBin Sun, email: [email protected]

Keywords: HPV, lung cancer, prognosis, meta-analysis

Received: July 26, 2016    Accepted: February 08, 2017    Published: February 24, 2017


Although a number of studies have investigated the association between human papillomavirus (HPV) and lung cancer prognosis, the results remain inconsistent. We therefore conducted a meta-analysis of epidemiologic studies to address this issue. Searches of the MEDLINE and EMBASE electronic databases from their inception until June 30, 2016 yielded nine studies involving a total of 1,205 lung cancer cases that were used to conduct the meta-analysis. Study-specific risk estimates were pooled using a random-effects model. The pooled hazard ratio (HR) comparing HPV-positive to HPV-negative cancers 1.00 (95% confidence interval (CI): 0.78-1.28) was not significantly correlated with overall survival. However, lung adenocarcinoma patients with HPV infections exhibited a survival benefit compared to those without HPV infection (HR=0.69, 95% CI: 0.50-0.96). This meta-analysis suggests HPV infection is a prognostic marker in lung adenocarcinoma. To further elucidate the epidemiology and pathogenesis of HPV infections in lung cancer, future large prospective studies are encouraged to stratify survival analysis based on the pathological type and clinical stage of the cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15671